Sign in

    Matthew Luchini

    Research Analyst at BMO Capital Markets

    Matthew Luchini's questions to Boundless Bio (BOLD) leadership

    Matthew Luchini's questions to Boundless Bio (BOLD) leadership • Q3 2019

    Question

    Matthew Luchini of BMO Capital Markets sought to confirm if there were any areas of misalignment with the FDA on nonclinical or CMC aspects of the DMD program and asked if the AT702 IND filing was dependent on the NCH IND.

    Answer

    COO Natalie Holles stated there were no areas of obvious misalignment with the FDA, noting the agency was enthusiastic about the platform approach. She highlighted the strength of their construct-agnostic manufacturing platform. She also clarified that the AT702 IND filing is not dependent on the NCH IND, as it is supported by its own complete dose-finding and toxicology studies.

    Ask Fintool Equity Research AI

    Matthew Luchini's questions to Boundless Bio (BOLD) leadership • Q2 2019

    Question

    Matthew Luchini from BMO Capital Markets asked about changes to secondary endpoints for the MTM pivotal cohort, the status of trial preparations for the Pompe program, and the plan for sharing data from the initial DMD patients treated at NCH.

    Answer

    Chairman and CEO Matt Patterson highlighted a new key secondary endpoint for the MTM trial: the ability to sit unassisted for 30 seconds. He confirmed that trial preparations for the Pompe program are well underway with KOLs engaged. He clarified that the focus for the DMD program should be on the forthcoming data from Audentes' own improved product.

    Ask Fintool Equity Research AI

    Matthew Luchini's questions to Boundless Bio (BOLD) leadership • Q4 2018

    Question

    Matthew Luchini of BMO Capital Markets asked about the timing for preclinical Pompe data disclosure and requested an update on the number of patients dosed in the Crigler-Najjar program.

    Answer

    President and CEO Matthew Patterson responded that while a plan is still being formulated, he hopes to share preclinical Pompe data in the fall, balancing transparency with competitive strategy. For the Crigler program, he confirmed that one patient was dosed in the prior year, but no additional patients have been dosed to date.

    Ask Fintool Equity Research AI

    Matthew Luchini's questions to InflaRx (IFRX) leadership

    Matthew Luchini's questions to InflaRx (IFRX) leadership • Q3 2019

    Question

    Matthew Luchini of BMO Capital Markets asked how the open-label extension data informs the company's strategy for proper IFX-1 dosing in future trials. He also inquired if patients required antibiotics for flares during the study and asked about the publication plans for the SHINE and Phase IIa study data.

    Answer

    Executive Niels Riedemann responded that while a definitive future dosing strategy depends on regulatory discussions, the company has a very good understanding of an effective dose. He noted the open-label data surprisingly showed that a low dose (800mg every 4 weeks) was relatively successful for maintenance. He clarified that while certain baseline antibiotics were allowed per KOL advice to maintain stability, it did not impact results. The company plans to publish the full SHINE study results after the database is locked early next year.

    Ask Fintool Equity Research AI